您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > Splitomicin(Splitomycin)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Splitomicin(Splitomycin)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Splitomicin(Splitomycin)图片
CAS NO:5690-03-9
规格:≥98%
包装与价格:
包装价格(元)
5mg电议
25mg电议
50mg电议
100mg电议
250mg电议
500mg电议

产品介绍
理化性质和储存条件
Molecular Weight (MW)198.22
FormulaC13H10O2
CAS No.5690-03-9
Storage-20℃ for 3 years in powder form
-80℃ for 2 years in solvent
Solubility (In vitro)DMSO: 39 mg/mL (196.0 mM)
Water: <1 mg/mL
Ethanol: 39 mg/mL (196.0 mM)
Other info

Chemical Name: 1H-benzo[f]chromen-3(2H)-one

InChi Key: ISFPDBUKMJDAJH-UHFFFAOYSA-N

InChi Code: InChI=1S/C13H10O2/c14-13-8-6-11-10-4-2-1-3-9(10)5-7-12(11)15-13/h1-5,7H,6,8H2

SMILES Code: O=C1CCC2=C3C=CC=CC3=CC=C2O1

SynonymsSplitomicin; Splitomycin
实验参考方法
In Vitro

In vitro activity: Splitomicin inhibits Sir2p deacetylase activity by altering or blocking access to the acetylated histone binding pocket. Splitomicin inhibits platelet aggregation induced by thrombin, collagen, AA and U46619 via inhibition of cyclic AMP phosphodiesterase activity and subsequent inhibition of intracellular Ca(++) mobilization, TXB2 formation and ATP release.


Kinase Assay: Splitomicin (Splitomycin) is a selective Sir2p inhibitor. Splitomicin inhibits NAD+-dependent HDAC activity of Sir2 protein. Splitomicin induces dose-dependent inhibition of HDAC in the yeast extract with an IC50 of 60 μM


Cell Assay: Splitomicin (10-333 μM; 24 hours) elicits antiproliferative effects in MCF-7 and H1299 cells in a dose-dependent manner in colony formation assay. Splitomicin (33 μM) fails to decrease the number of colonies, but Splitomicin (100 and 333 μM) effectively inhibits colony formation in MCF-7 and H1299 cells

In VivoIn a photochemical injury mouse model, splitomicin (80 mg/kg/d i.p.) enhances tissue factor activity in the arterial vessel wall and promotes carotid artery thrombus formation.
Animal modelCarotid artery thrombosis mouse model
Formulation & DosageFormulated in 0.5% methylcellulose; 80 mg/kg; i.p. injection
References

Proc Natl Acad Sci U S A. 2001 Dec 18;98(26):15113-8; Thromb Res. 2009 Jun;124(2):199-207; J Biol Chem. 2014 Sep 12;289(37):25890-906.